We report the first case to our knowledge of donor-derived myelodysplasia following nonmyeloablative transplantation without radiotherapy conditioning in an adult. A 54-year-old man with a 5-year history of multiply treated refractory follicular non-Hodgkin's lymphoma was transplanted with a matched sibling donor (sister) in January 2000. Previous chemotherapeutic regimens included chlorambucil/dexamethasone, fludarabine, CHOP, cyclophosphamide, ifosfamide/adriamycin, carboplatin/ cytarabine, and ESHAP. No radiotherapy had been required. Conditioning for stem cell transplantation was with BEAM-alemtuzamab, with methotrexate and cyclosporine as graft-versus-host disease prophylaxis. 1 He was transplanted with 3.8 Â 10 6 CD34 þ /kg unmanipulated peripheral blood stem cells achieving neutrophils 40.5 Â 10 9 /l by day þ 17 and platelets 420 Â 10 9 /l by day þ 31. His cyclosporin was gradually weaned from day þ 100 and stopped after 5 months. The donor had longstanding alopecia areata, and 10 months after donating peripheral blood stem cells, developed breast cancer.
At 5 months following the procedure, the patient remained cytopenic with haemoglobin concentration (Hb) 9.5 g/l, white cell count (WBC) 1.0 Â 10 9 /l, neutrophils 0.3 Â 10 9 /l, and platelets 21 Â 10 9 /l. Bone marrow showed good engraftment with full donor chimerism and no evidence of relapse. He was regrafted without any preparative conditioning with CD34 selected donor cells 1.81 Â 10 6 CD34 þ /kg, CD3 þ 1.4 Â 10 3 /kg. After 15 days he developed total alopecia.
At 2 months after his CD34 cell 'top up', he remained cytopenic with neutrophils 0.3 Â 10 9 /l and platelets 47Â10 9 / l. He received granulocyte-colony stimulating factor (G-CSF) support but remained cytopenic. Bone marrow was cellular. Bone marrow fibroblast colony (CFU-F) growth was markedly reduced at 44 CFU colonies/10 6 mononuclear cells (control: mean 139 colonies/10 6 , range 99-180). There was no evidence of disease relapse. A trial of intravenous immunoglobulin infusions failed to improve the cytopenias. During this period, he developed presumed aciclovir-resistant herpetic mouth ulcers, which required prolonged treatment with Foscarnet and Cidofovir. A repeat CT scan 13 months post transplant showed mild splenomegaly but no active lymphoma. Splenectomy was performed in April 2001 to obtain tissue and with the hope that the cytopenias may be due to peripheral destruction.
Following splenectomy blood counts normalised. The spleen was histologically normal. He remained well and in full time employment.
In September 2003, he was again noted to be mildly cytopenic; Hb 11.9 g/dl, WBC 3.5 Â 10 9 /l and platelets 108 Â 10 9 /l. Haematinics were normal. A bone marrow biopsy showed trilineage dysplasia with o5% blasts. Cytogenetics showed a female karyotype and monosomy 7 (46,XX,À7, þ mar A CT scan performed at this stage showed an 11 cm mesenteric mass, which was thought to represent relapsed lymphoma. He received rituximab, vincristine and prednisolone (R-VP) for the relapsed lymphoma. Cyclophosphamide was omitted due to progressive cytopenias. There was an initial symptomatic improvement and four courses of R-VP were given, achieving a partial response. Blood counts remained stable, but repeat bone marrow cytogenetic analysis showed clonal expansion and evolution; (46,XX,À7,
. After 4 months, his WBC count rose and he became more thrombocytopenic. Bone marrow aspirate showed AML transformation. Intensive chemotherapy was considered inappropriate, and he was treated with outpatient subcutaneous low-dose cytarabine but died of resistant disease.
Few cases of donor-derived secondary MDS have been reported, 2 and none following a nonmyeloablative transplant. Most cases of donor-derived leukaemia are reported following radiotherapy conditioning. Possible mechanisms of donor-derived MDS include transfection of abnormal genetic material from recipient cells or a 'by-stander' effect from abnormal stroma. 2 The reduced in vitro fibroblast growth in our patient is suggestive of a stromal abnormality. The development of breast cancer in the donor raises the possibility of a familial genetic susceptibility to malignant change. An additional possibility is failure of immune surveillance and it is of interest that our patient's lymphoma relapsed at the time of onset of donor-derived myelodysplasia, suggesting a general loss of tumour surveillance rather than purely loss of graft-versus-lymphoma capability within the donor haematopoietic system. 
